Short interest in Nurix Therapeutics Inc (NASDAQ:NRIX) decreased during the last reporting period, falling from 12.17M to 12.16M. This put 18.75% of the company's publicly available shares short.

FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

In addition, Nurix continues to make significant progress with our pipeline of degrader-based drugs for the treatment of autoimmune disease and inflammation. Most recently we announced that Sanofi ...

Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics ...

Most recently we announced that Sanofi exercised its option to exclusively license an undisclosed Nurix program targeting a previously undruggable transcription factor that is a central regulator ...

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.76 per share a year ago.